TIDHI Innovation Inc.
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD) (NCT07245394) | TIDHI Innovation Inc. | 2026-01-29 |
| TIDHI Mental Health in IBD Patients Study (NCT07013578) | TIDHI Innovation Inc. | 2025-07-22 |
Track TIDHI Innovation Inc. automatically
Every clearance here is in the API, with alerts when new ones post.